Opaganib, an oral small molecule pill, shows potential as a nuclear radiation injury therapeutic for homeland security medical countermeasures and antitumor radiotherapy. The compound protects normal tissue from radiation damage and improves antitumor activity and response to chemoradiation.
RedHill Biopharma's Talicia demonstrates high potential for H. pylori eradication while minimizing systemic antibiotic exposure, outperforming generic rifabutin regimens. Movantik data shows improved patient quality of life and symptom improvement in opioid-induced constipation.
New data analyses from RedHill's Talicia H. pylori eradication clinical trials program showed high eradication rates and favorable safety and efficacy profiles in patients with diabetes. The study found that Talicia maintained high eradication rates of 91.7% and 84.1% in patients with and without diabetes, respectively.
A new study reveals widespread prescribing of clarithromycin-based regimens for H. pylori infection, defying increasing resistance and suboptimal eradication rates. Talicia, a rifabutin-based therapy, offers an alternative with higher eradication rates and fewer concerns over resistance.
The global Phase 2/3 study with opaganib in patients hospitalized with severe COVID-19 pneumonia has completed patient treatment and follow-up. The company expects to report top-line results in the coming weeks, which will determine the efficacy of opaganib in treating COVID-19.
Opaganib was shown to reduce supplemental oxygen support, improve discharge time and be well-tolerated in patients with COVID-19 pneumonia. The study's findings suggest a potential role of SK2 inhibition in combating the effects of the virus.
RedHill Biopharma has completed enrollment and randomized the last patient in its global Phase 2/3 study of orally-administered opaganib for treating severe COVID-19. The study captured outcomes such as breathing room air without oxygen support by Day 14, hospital discharge time, and intubation rates.
Preliminary data from the non-powered U.S. Phase 2 study showed that orally-administered opaganib was safe and demonstrated consistent trends of greater improvement in reducing oxygen requirement across key primary and secondary efficacy outcomes. The opaganib-treated arm demonstrated a greater improvement in reaching room air, reducti...
The global Phase 2/3 study with orally-administered opaganib in patients hospitalized with severe COVID-19 pneumonia has received a second unanimous recommendation to continue, based on an analysis of unblinded safety data from the first 155 patients treated for 14 days. Enrollment is over 60% complete and top-line data expected in Q1/...
RedHill's P2/3 COVID-19 candidate Opaganib has demonstrated reduced thrombosis in a preclinical model of ARDS. The study showed opaganib reduced blood clot length, weight, and total thrombus score in patients with severe respiratory distress syndrome induced by SARS-CoV-2.